Effects of the protease inhibitor antipain on cell malignant transformation

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 589-596

  Vaccari, Monica ^a,b   Argnani, Alessandra ^a   Horn, Wolfango ^a   Silingardi, Paola ^a   Giungi, Monica ^a   Mascolo, Maria Grazia ^a   Bartoli, Silvana ^b   Grilli, Sandro ^b   Colacci, Annamaria ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antipain; Chemical transformation; Chemoprevention; Invasion; Migration

Indexed keywords

1,2 DIBROMOETHANE; 3 METHYLCHOLANTHRENE; ANTIPAIN; CARCINOGEN; GELATINASE; METALLOPROTEINASE; PROTEINASE; PROTEINASE INHIBITOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CELL INVASION; CELL STRAIN 3T3; CELL TRANSFORMATION; CHEMOTAXIS; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

3T3 CELLS; ANIMALS; ANTICARCINOGENIC AGENTS; ANTIPAIN; CELL TRANSFORMATION, NEOPLASTIC; MICE; PROTEASE INHIBITORS;

EID: 0344075951     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Stoner GD, Morse MA and Kelloff GJ: Perspective in cancer chemoprevention. Env Health Perspect 105: 945-954, 1997.
2. Das S and Mukhopadhyay P: Protease inhibitors in chemoprevention of cancer. Acta Oncologica 33: 859-865, 1994.
3. Troll W, Wiesner R and Frenkel K: Anticancerogenic action of protease inhibitors. Adv Cancer Res 49: 265-283, 1987.
4. Kennedy AR: Prevention of carcinogenesis by protease inhibitors. Cancer Res 54 (suppl.): 1999-2005, 1994.
5. DeClerck YA and Imren S: Protease inhibitors: role and potential therapeutic use in human cancer. Eur J Cancer 30A: 2170-2180, 1994.
6. Yamasaki H, Ashby J, Bignami M, Jongen W, Linnainmaa K, Newbold RF, Nguyen-Ba G, Parodi S, Rivedal E, Schiffmann D, Simson JWIM and Vasseur P: Nongenotoxic carcinogens: development of detection methods based on mechanisms: a European project. Mutat Res 353: 47-63, 1996.
7. IARC/NCI/EPA Working Group: Cellular and molecular mechanisms of cell transformation and standardisation of transformation assay of established cell lines for the prediction of carcinogenic chemicals: overview and recommended protocols. Cancer Res 45: 2395-2399, 1985.
8. Matthews EJ, Spalding JW and Tennant RW: Transformation of BALB/c 3T3 Cells: V. Transformation Responses of 168 Chemicals Compared with Mutagenicity in Salmonella and Carcinogenicity in Rodent Bioassays. Environ Health Persp 101 (Suppl. 2): 347-482. 1993.
9. Kakunaga T: Critical review of the use of established cell lines for in vitro cell transformation. In: Kakunaga T e Yamasaki H (eds.) "Transformation assay of established cell lines: mechanisms and application". IARC Sci Publ, 67 International Agency for Research on Cancer, Lyon, 55-73, 1985.
10. Matthews EJ: Transformation of BALB/c 3T3 Cells: II. Investigation of Experimental Parameters that Influence Detection of Benzo[a] pyrene-Induced Transformation. Environ Health Persp 101 (Suppl. 2): 293-310, 1993.
11. Umezawa H and Ayoagi T: Activities of proteinase inhibitors of microbial origin. In: Barret AJ (ed). Proteinase in mammalian cells and tissues. North Holland Publishing Company: 637-662, 1979.
12. Afzal V, Wiencke JK and Wolff S: Antipain-mediated suppression of x-ray-induced chromosomal aberrations in human lymphocytes. Carcinogenesis 10: 1193-1196, 1989.
13. Kleinman HK, McGarvey ML, Hassel JR, Star VL, Cannon FB, Lauric GW and Martin GR: Basement membrane complexes with biological activity. Biochemistry 25: 312-318, 1986.
14. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowsky JM and McEwan RM: A rapid in vitro assay for quantitating the invasive potential of tumour cells. Cancer Res 47: 3239-3245, 1987.
15. Heussen C and Dowdle EB: Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102: 196-202, 1980.
16. Kuroki T and Drevon C: Inhibition of chemical transformation in C3H/10T1/2 cells by protease inhibitors. Cancer Res 39: 2755-2761, 1979.
17. Perocco P, Colacci A, Santucci AM, Vaccari M and Grilli S: Transforming activity of ethylene dibromide in BALB/c 3T3. Res Comm Chem Pathol Pharmacol 73: 159-172, 1991.
18. Colacci A, Perocco P, Vaccari M, Da Vià C, Silingardi P, Manzini E, Horn W, Bartoli S and Grilli S: 1,2-Dibromoethane as initiating agent for cell transformation. Jpn J Cancer Res 86: 168-173, 1995
19. Colacci A, Vaccari M, Perocco P, Da Vià C, Silingardi P, Manzini E, Horn W and Grilli S: Enhancement of BALB/c 3T3 cells transformation by 1,2-dibromoethane promoting effect. Carcinogenesis 17: 225-231, 1996.
20. Adatia R, Albini A, Colacci A, De Giovanni C, Nanni P, Giunciuglio D, Parodi S, Grilli S and Perocco P: Induction of chemotactic and invasive phenotype in BALB/c 3T3 cells by 1,2-dibromoethane transformation. Invasion Metastasis 13: 234-243, 1993.
21. Macdonald TL: Chemical mechanism of halocarbon metabolism. CRC Crit Rev Toxicol 11: 85-120, 1983.
22. Koga N, Inskeep PB, Harris TM and Guengerich FP: S-[2-(N7-guanyl)ethyl]glutathione, the major DNA adduct formed from 1,2-dibromoethane. Biochemistry 25: 2912-2918, 1986.
23. Kennedy AR, Radner BS, and Nagasawa H: Protease inhibitors reduce the frequency of spontaneous chromosome abnormalities in cells from patients with Bloom syndrome. Proc Natl Acad Sci USA 81: 1827-1830, 1984.
24. Baturay N and Kennedy AR: Pyrene acts as a cocarcinogen with the carcinogens benzo(a)pyrene, beta-propiolactone and radiation in the induction of malignant transformation in cultured mouse fibroblasts, soybean extract-containing the Bowman-Birk inhibitor acts as an anticarcinogen. Cell Biol Toxicol: 2: 21-32, 1986.
25. Kennedy AR: The conditions for the modification of radiation transformation in vitro by a tumour promoter and protease inhibitors. Carcinogenesis 6: 1441-1445, 1985.
26. StClair WH: Suppression of 3-methylcholanthrene-induced cellular transformation by timed administration of the Bowman-Birk protease inhibitor. Carcinogenesis 12: 935-937, 1991.
27. Chang JD, Li J-H, Billings PC and Kennedy AR: Effects of protease inhibitors on c-Myc expression in normal and transformed C3H 1ØT1/2cell lines. Mol Carcinog 3: 226-232, 1990.
28. Caggana M and Kennedy A: c-fos mRNA levels are reduced in the presence of antipain and the Bowman-Birk inhibitor. Carcinogenesis 10: 2145-2148, 1989.
29. Garte SJ, Currie DD and Troll W: Inhibition of H-ras oncogene transformation of NIH3T3 cells by protease inhibitors. Cancer Res 47: 3159-3162, 1987.
30. Cox L, Motz J, Troll W and Garte S: Antipain induced suppression of oncogene expression in H-ras transformed NIH 3T3 cells. Cancer Res 51: 4810-4814, 1991.
31. Clawson GA: Protease inhibitors and carcinogenesis: a review. Cancer Investigation 14(6): 597-608, 1996.
32. Billings PC, Caren JA, Keller-McGangi CE, Goldberg AL and Kennedy AR: A serine protease activity in C3H10T1/2 cells is inhibited by anticancerogenic protease inhibitors. Proc Natl Acad Sci USA 84: 4801-4805, 1987.
33. Mignatti P and Rifkin DB: Biology and biochemistry of proteinases in tumour invasion. Physiological Reviews 73: 161-195, 1993.
34. Long DL, Quigley JP, Troll W and Kennedy AR: Protease inhibitor antipain suppresses 12-O-tetradecanoyl-phorbol-13-acetate induction of plasminogen activator in transformable mouse embryo fibroblasts. Carcinogenesis 2: 933-936, 1981.
35. Bjornland K, Buo L, Kjonniksen I, Larsen M, Fodstad O, Johansen H T and Aasen AO: Cysteine proteinase inhibitors reduce malignant melanoma cell invasion in vitro. Anticancer Res 16: 1627-1632, 1996.
36. Kanemoto T, Martin GR, Hamilton TC and Fridman R: Effects of synthetic peptides and protease inhibitors on the interaction of a human ovarian cancer cell line (NIH: OVCAR-3) with a reconstituted basement membrane (Matrigel). Inv Met 11: 84-92, 1991.